ENG and hereditary hemorrhagic telangiectasia: Because several antiangiogenic therapies have been used in HHT patients (Lebrin et al., 2010; Dupuis-Girod et al., 2012, 2016; Albiñana et al., 2012) to inhibit vascular bleeding produced by the rupture of AVMs, we analyzed whether sEng could also modulate the occurrence of AVMs formed in an established mouse model of HHT1 (Mahmoud et al., 2010; Tual-Chalot et al., 2015).